OR-GUROBI-OPTIMIZATION
2.6.2022 23:28:10 CEST | Business Wire | Press release
Gurobi Optimization, LLC , creator of the world’s fastest mathematical optimization solver, announced the launch of their new educational game that aims to show players the power of optimization. The “Burrito Optimization Game” is a free, web-based app designed for data science and operations research students, as well as anyone who stands to benefit from mathematical optimization. In addition to demonstrating the value of optimization, the game also proves its difficulty, as well as the importance of algorithms and solvers in finding an optimal solution.
Gurobi created the Burrito Optimization Game in collaboration with Dr. Larry Snyder of Lehigh University, who explains that at the time he and Gurobi started work on the project, there were several other projects in the data science community that used the premise of locating a hypothetical new restaurant. The projects scored possible locations based on demographics, demand, and other data science factors.
“As optimizers, we know it can be easy to pick the single best location once you have a score, but if you need to pick five, ten, or fifty locations, especially when there are thousands to choose from, that becomes a very different kind of problem,” says Dr. Snyder. “So we decided to use this as a way to introduce the optimization story, hoping that the idea of first coming up with a score for each location and then putting that into an optimization context would resonate, even for data scientists who hadn’t seen the restaurant examples.”
Gurobi’s game is based on a classic facility location problem and allows players to choose the best locations for a “Guroble” food truck, with the goal of maximizing their total profit. For each level, players are presented with a new story, with added complexity, and a set of data to help them make decisions. The data provided typically includes the cost of each truck, the price of ingredients, and the total sales revenue for each burrito sold, as well as scenarios that will impact decision-making—such as disruptions in the burrito ingredient supply chain, or weather conditions that impact a customer’s willingness to travel.
Players can drag and drop their Guroble trucks around an illustrated map, where they can see how many customers are in each building. The closer the truck is to a building, the more customers from that building will be willing to walk to the truck to buy a burrito. Players can see how their profits adjust when they drag and drop the truck to a different location, highlighting the importance of trade-offs in complex decision-making.
Once a player is satisfied with their placement of the trucks, Gurobi will solve the problem and find the optimal solution within a fraction of a second. Players can then see how far they were from the optimal solution in terms of total profit.
The game also provides tips along the way to further the learning experience once players submit their solution. For example, players might be notified that a certain part of the city is underserved, or they’ll see a hint that their solution has the optimal number of trucks, but in the wrong locations.
In subsequent rounds, the game introduces uncertainties for an added challenge. Players need to build their solutions based off of forecasts rather than actual demand in this game—a concept that’s very familiar for data science students. For example, there might be 25 potential customers forecast in a building, but the actual amount could be off by up to five customers. Error bars indicate how far in either direction the actual demands might be.
“What we’re hoping to convey is that if you were to try optimization by trial and error, it’s not only tedious and time-consuming, but it’s also hard to make good decisions,” explains Dr. Snyder. “We also wanted to make clear that although optimization is hard, it’s a mature scientific field with robust commercial and open-source software that can solve these problems for us.”
“We launched this a little while ago, and the early feedback has been extremely positive,” explained Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization. “One common response from optimization professionals is excitement about the prospect of having a simple, entertaining way to show the people they work with the sorts of problems optimization can solve and the power that it brings.”
The Burrito Optimization Game is available on Gurobi’s website , accompanied by a series of resources that highlight intended educational takeaways and explain how instructors can teach the game in a classroom setting or how players can use the game on their own.
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver—the Gurobi Optimizer—which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support—so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
